Humana sues HHS over Medicare Advantage audits
The payer, which brings in the bulk of its revenue from Medicare, is fighting back against a rule finalized earlier this year to claw back overpayments in the increasingly popular MA program.
Uncategorized
23andMe wins FDA clearance to test for expanded set of BRCA cancer risk variants
The new version of the test can report more cancer-related gene mutations, and 23andMe can add variants in the future under an agreement with the FDA.
23andMe wins FDA clearance to test for expanded set of BRCA cancer risk variants Read More »
Medtronic sued for allegedly sharing ‘treasure trove’ of diabetes patient data with Google
The plaintiff said disclosures to Google are “particularly problematic” because his use of Gmail meant his personal information was “automatically linked to his real identity.”
Illumina names Agilent’s Jacob Thaysen as its next CEO
The appointment comes less than three months after former CEO Francis deSouza stepped down following a proxy battle.
Illumina names Agilent’s Jacob Thaysen as its next CEO Read More »
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously announced acquisition of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings (the “Asset Purchase”).
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
Tris Pharma, Inc. (Tris), today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19.
Biofidelity announces the commercial launch of ASPYRE-Lung in the US
Biofidelity, a revolutionary genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world, today announced the commercial launch of ASPYRE®-Lung in the US.
Biofidelity announces the commercial launch of ASPYRE-Lung in the US Read More »
Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries
Revvity, Inc. (NYSE: RVTY) today debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems.
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
Enveric Biosciences today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,087, titled “C-4 Carboxylic Acid Substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s EVM201 Series and lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.